Systemic Octreotide Therapy in Prevention of Gastrointestinal Bleeds Related to Arteriovenous Malformations and Obscure Etiology in Atrial Fibrillation
JournalJACC: Clinical Electrophysiology
MetadataShow full item record
AbstractObjectives: The present study describes the use of octreotide (OCT) in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) who have gastrointestinal (GI) bleeding related to arteriovenous malformations (AVMs), as well as its effect on OAC tolerance and subsequent rebleeding. Background: AVMs cause significant GI bleeding, especially in patients with AF who are receiving OAC for stroke prevention. OCT has been shown to minimize recurrent GI bleeds related to AVMs. Methods: In a multicenter, observational study, 38 AF patients with contraindications to OAC because of AVM-related GI bleeding were started on 100 μg of subcutaneous OCT twice daily. OAC was resumed in all patients within 48 h. Incidence of recurrent GI bleeds was calculated, and hemoglobin levels were recorded at enrollment and at 3 and 6 months’ follow-up. Results: After a median follow-up of 8 months, 36 patients (mean age 69 ± 8.0 years; mean CHA2DS2-VASc score 3 ± 1 and mean HAS-BLED score 3 ± 1) were available for analysis. All were able to successfully resume OAC, and 28 of 36 (78%) remained on OAC at the conclusion of the study, whereas 8 underwent left atrial appendage closure with subsequent OAC discontinuation. No systemic thromboembolic events occurred in follow-up. Of the 28 patients who continued receiving OAC, 19 (68%) were free of recurrent GI bleed, 4 had minor GI bleeds, 4 required transfusion, and 1 required colectomy for GI bleeding. Mean hemoglobin levels in all patients receiving OAC were significantly higher at 3- and 6-month follow-up than at baseline (p < 0.001). Conclusions: Subcutaneous OCT therapy is an attractive option in AF patients receiving OAC who have AVM-related GI bleeds. It allows successful reinitiation of OAC as a bridge to left atrial appendage exclusion or short-term relief from bleeding. Copyright 2017
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85029146806&doi=10.1016%2fj.jacep.2017.04.022&partnerID=40&md5=ff0ea2cb23f8189821401c484118b514; http://hdl.handle.net/10713/10002
- Initial Experience With High-Risk Patients Excluded From Clinical Trials: Safety of Short-Term Anticoagulation After Left Atrial Appendage Closure Device.
- Authors: Barakat AF, Hussein AA, Saliba WI, Bassiouny M, Tarakji K, Kanj M, Jaber W, Rodriguez LL, Grimm R, Hussain MS, Russman A, Uchino K, Wisco D, Rasmussen P, Bain M, Vargo J, Zuccaro G, Gottesman D, Lindsay BD, Wazni OM
- Issue date: 2016 Jun
- Management of Stroke risk in atrial fibrillation patients with bleeding on Oral Anticoagulation Therapy-Role of Left Atrial Appendage Closure, Octreotide and more.
- Authors: Dar T, Yarlagadda B, Vacek J, Dawn B, Lakkireddy D
- Issue date: 2017 Dec
- The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
- Authors: Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY
- Issue date: 2013 Dec 10
- Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation.
- Authors: Wiebe J, Bertog S, Franke J, Wettstein O, Lehn K, Hofmann I, Vaskelyte L, Sievert H
- Issue date: 2014 Apr 1
- Percutaneous left atrial appendage closure for stroke prevention.
- Authors: De Backer O, Loupis AM, Ihlemann N, Vejlstrup NG, Søndergaard L, Franzen OW
- Issue date: 2014 Aug